{
    "info": {
        "nct_id": "NCT04208958",
        "official_title": "Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer",
        "inclusion_criteria": "* Patients with advanced or metastatic cancer who had received no more than 3 lines of prior systemic therapy for advanced/metastatic disease.\n* Histologically diagnosed advanced (unresectable) or metastatic cancer with at least one measurable lesion as per RECIST 1.1\n* Tumor lesions amenable for biopsy, if deemed safe by the investigator\n* Toxicity from prior cancer therapy should have resolved to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 (excluding alopecia and neuropathy, where up to Grade 2 residual was allowed)\n\nPartial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with immune checkpoint inhibitor (iCPI) (Note: this criterion did not apply to patients with melanoma)\n* Receipt of any conventional or investigational systemic anti-cancer therapy within 21 days prior to the first dose of vancomycin\n* Concurrent chemotherapy, immunotherapy, biologic, or hormonal anti-cancer therapy. Agents such as bisphosphonates or denosumab were acceptable as prophylaxis for bone metastasis.\n* Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment\n* Patients with an active, known or suspected autoimmune disease. Patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment were permitted to enroll.\n* Patients with known active hepatitis (e.g., hepatitis B or C) NOTE: Patients with previously treated hepatitis B or C were permitted to enroll if there was evidence of documented resolution of infection.\n* Received a fecal transplant, spore or other preparation of fecal material, isolated bacterial products, genetically modified bacteria, or VE800",
        "miscellaneous_criteria": "Partial"
    },
    "inclusion_lines": [
        {
            "line": "* Patients with advanced or metastatic cancer who had received no more than 3 lines of prior systemic therapy for advanced/metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "advanced or metastatic cancer",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no more than 3 lines of prior systemic therapy for advanced/metastatic disease",
                    "criterion": "prior systemic therapy lines for advanced/metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically diagnosed advanced (unresectable) or metastatic cancer with at least one measurable lesion as per RECIST 1.1",
            "criterions": [
                {
                    "exact_snippets": "Histologically diagnosed advanced (unresectable) or metastatic cancer",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "histologically diagnosed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced (unresectable)",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one measurable lesion as per RECIST 1.1",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurement_standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor lesions amenable for biopsy, if deemed safe by the investigator",
            "criterions": [
                {
                    "exact_snippets": "Tumor lesions amenable for biopsy",
                    "criterion": "tumor lesions",
                    "requirements": [
                        {
                            "requirement_type": "amenability for biopsy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if deemed safe by the investigator",
                    "criterion": "biopsy procedure",
                    "requirements": [
                        {
                            "requirement_type": "safety as determined by investigator",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Partial",
            "criterions": [
                {
                    "exact_snippets": "Partial",
                    "criterion": "disease response",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": "partial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Toxicity from prior cancer therapy should have resolved to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1 (excluding alopecia and neuropathy, where up to Grade 2 residual was allowed)",
            "criterions": [
                {
                    "exact_snippets": "Toxicity from prior cancer therapy should have resolved to Common Terminology Criteria for Adverse Events (CTCAE) Grade ≤ 1",
                    "criterion": "toxicity from prior cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity (CTCAE grade)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding alopecia and neuropathy, where up to Grade 2 residual was allowed",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity (CTCAE grade)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding alopecia and neuropathy, where up to Grade 2 residual was allowed",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity (CTCAE grade)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with known active hepatitis (e.g., hepatitis B or C) NOTE: Patients with previously treated hepatitis B or C were permitted to enroll if there was evidence of documented resolution of infection.",
            "criterions": [
                {
                    "exact_snippets": "Patients with known active hepatitis (e.g., hepatitis B or C)",
                    "criterion": "active hepatitis infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with previously treated hepatitis B or C were permitted to enroll if there was evidence of documented resolution of infection.",
                    "criterion": "previously treated hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "resolution of infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of any conventional or investigational systemic anti-cancer therapy within 21 days prior to the first dose of vancomycin",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any conventional or investigational systemic anti-cancer therapy within 21 days prior to the first dose of vancomycin",
                    "criterion": "systemic anti-cancer therapy receipt",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to first dose of vancomycin"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "conventional",
                                "investigational"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a fecal transplant, spore or other preparation of fecal material, isolated bacterial products, genetically modified bacteria, or VE800",
            "criterions": [
                {
                    "exact_snippets": "Received a fecal transplant",
                    "criterion": "fecal transplant",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "spore or other preparation of fecal material",
                    "criterion": "spore or other preparation of fecal material",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "isolated bacterial products",
                    "criterion": "isolated bacterial products",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "genetically modified bacteria",
                    "criterion": "genetically modified bacteria",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "VE800",
                    "criterion": "VE800",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with immune checkpoint inhibitor (iCPI) (Note: this criterion did not apply to patients with melanoma)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with immune checkpoint inhibitor (iCPI)",
                    "criterion": "prior treatment with immune checkpoint inhibitor (iCPI)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "this criterion did not apply to patients with melanoma",
                    "criterion": "melanoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "exemption from iCPI prior treatment criterion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent chemotherapy, immunotherapy, biologic, or hormonal anti-cancer therapy. Agents such as bisphosphonates or denosumab were acceptable as prophylaxis for bone metastasis.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent chemotherapy, immunotherapy, biologic, or hormonal anti-cancer therapy.",
                    "criterion": "concurrent anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "therapy_types",
                            "expected_value": [
                                "chemotherapy",
                                "immunotherapy",
                                "biologic therapy",
                                "hormonal anti-cancer therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Agents such as bisphosphonates or denosumab were acceptable as prophylaxis for bone metastasis.",
                    "criterion": "use of bisphosphonates or denosumab as prophylaxis for bone metastasis",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment",
                    "criterion": "transfusion (platelets or red blood cells)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with an active, known or suspected autoimmune disease. Patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment were permitted to enroll.",
            "criterions": [
                {
                    "exact_snippets": "Patients with an active, known or suspected autoimmune disease.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "type I diabetes mellitus ... permitted to enroll",
                    "criterion": "type I diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypothyroidism only requiring hormone replacement ... permitted to enroll",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "hormone replacement only"
                        }
                    ]
                },
                {
                    "exact_snippets": "skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment were permitted to enroll",
                    "criterion": "skin disorders (vitiligo, psoriasis, alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "not requiring systemic treatment"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Partial",
            "criterions": [
                {
                    "exact_snippets": "Partial",
                    "criterion": "disease response",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": "partial"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}